---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000033"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:48:46.860225+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma issues $10M convertible note to Daewoong, appoints Daewoong CEO to board

## Summary
- Issued $10M senior secured convertible note to Daewoong on April 12, 2024, with 15.79% annual interest and maturity April 12, 2027.
- Proceeds will support late-stage clinical development of ABP-450 and general working capital.
- Appointed Seongsoo Park (CEO of Daewoong) as Class III director, expanding board from five to six members.
- Note is identical in terms to the $5M convertible note issued March 24, 2024 under the same subscription agreement.
- Mr. Park will serve until the 2026 annual meeting; he brings industry and leadership experience.

## SEC filing metadata
- accession: 0001837607-24-000033
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/aeon-20240412x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000033
- JSON: https://secwatch.observer/filing/0001837607-24-000033.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000033.txt

## Key facts
- Debt Financings
  AEON Biopharma, Inc. incurred convertible notes of $10.0 million with Daewoong Pharmaceutical Co., LTD. at annual rate of 15.79% maturing April 12, 2027.
  - Instrument: convertible notes
  - Principal: $10.0 million
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Rate: annual rate of 15.79%
  - Maturity: April 12, 2027
  - Event: incurrence
  source text: on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm
- Executive change
  Seongsoo Park was appointed as Class III director at AEON Biopharma, Inc..
  - Action: appointed
  - Role: Class III director
  source text: the Board of Directors (the “Board”) of the Company appointed Seongsoo Park as a Class III director of the Board, effective as of April 12, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm
- Material Agreements
  AEON Biopharma, Inc. entered into Convertible Note with Daewoong Pharmaceutical Co., LTD. valued at $10.0 million (effective 2024-04-12).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Daewoong Pharmaceutical Co., LTD.
  - Value: $10.0 million
  - Effective: 2024-04-12
  source text: on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.